ArticleOrphanet journal of rare diseases2026
Transition from zinc salts to trientine tetrahydrochloride in a cohort of adult patients with Wilson disease: the ZICUP study.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron and Other Metal Ions in Human Health and Disease.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilson disease (WD) treatment aims to reduce copper accumulation in the liver and brain. Zinc salts (ZS) are often associated with gastrointestinal side effects, poor adherence, and reduced efficacy. Copper chelators, such as trientine tetrahydrochloride (TETA4), offer an alternative for patients who are intolerant or unresponsive to ZS. This observational study assesses the long-term efficacy and safety of switching from ZS to TETA4 in twenty WD patients (15 hepatic, 5 hepato-neurological) from the French WD Registry. Treatment goals included normalization of aminotransferases, stabilization or improvement of the liver (APRI, liver stiffness and liver ultrasonography; US) and the neurological (Unified Wilson’s Disease Rating Scale; UWDRS) involvement, Clinical Global Impression (CGI) severity scale, and achievement of copper balance targets. Assessments were performed at baseline and every 6 months for 3 years. Adverse events were recorded throughout the follow-up. The results revealed that the main reasons for switching were gastrointestinal intolerance and loss of efficacy with ZS; 60% had elevated ALT at baseline. TETA4 was initiated at a median dose of 412.5 mg (360–450) and titrated up to 750 mg/day (600–900 mg) to achieve the treatment goals. Over 3 years, no changes were observed in ALT, APRI, liver US, UWDRS and CGI scores. TETA4 was well tolerated. In conclusion, transitioning from ZS to TETA4 maintained clinical stability and adherence with a favorable safety profile. Dose adjustments suggest conversion ratios of ~1:6 elemental zinc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.